Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06285539
Other study ID # 2022-502968-20
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date March 2024
Est. completion date December 2026

Study information

Verified date February 2024
Source UMC Utrecht
Contact Anne Karien Marijnissen, Dr
Phone +887550459
Email a.c.a.marijnissen@umcutrecht.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need for new, more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs. Due to the role of type 1 interferon in both BD, IIM and IgG4-RD, JAK-STAT inhibition may be a promising treatment strategy in these conditions, because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors. Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date December 2026
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18 years of older - One of the following rare IMIDs: - Diagnosis of Behçet's disease without refractory life, organ or sight-threatening symptoms with active disease, defined as a BDCAF >2 (new BDCAF) or >15 (old BDCAF) or with active disease, based on clinical grounds (e.g. the need to start new or additional medication - Diagnosis of idiopathic inflammatory myopathy, according to diagnostic criteria: Dermatomyositis: Dermatomyositis Classification Criteria according to the European Neuromuscular Centre guidelines 201852 or anti-synthetase syndrome: Anti- synthetase syndrome Classification Criteria according to the European Neuromuscular Centre guidelines 200353, both with active disease, defined as a CDASI score of =5 or abnormal levels of at least 1 of the following enzymes: creatine kinase (= 4× upper limit of normal [ULN]), aldolase (=4 × ULN), lactate dehydrogenase (LDH =4 × ULN), aspartate transaminase (AST =4 × ULN), alanine aminotransferase (ALT =4 × ULN) or a MRI within the last 3 months indicative of active inflammation (e.g. edema signal pattern in affected proximal muscles) or active disease based on clinical grounds, e.g. the need to start new or additional medication - Diagnosis of IgG4-related disease, according to 2019 ACR/EULAR guidelines, with active disease, defined as: IgG4-related disease responder index >10 or active disease based on clinical grounds, e.g. the need to start new or additional medication - Refractory disease, defined as symptomatic disease that persists despite a 12-week trial of glucocorticoid therapy as well as lack of response to at least one other immunosuppressive agent such as methotrexate (MTX), mycophenolate mofetil (MMF), azathioprine (AZA) or rituximab or intolerance to standard-of-care treatment, as defined by the treating physician. - No evidence of active or latent or inadequately treated infection with mycobacterium tuberculosis (TB) as defined by all of the following: both a negative QuantiFERON-TB Gold (QFT-G) In-Tube test and a Mantoux tuberculin skin test performed at or within 3 months prior to screening and no signs suggestive of active TB infection as determined (and documented) by a qualified radiologist or pulmonologist as per local standard of care on a chest radiograph and no history of either untreated or inadequately treated latent or active TB infection. Exclusion Criteria: - Age <18 years - Age =65 years - Life expectancy less than 6 months - Juvenile DM, myositis overlapping with other autoimmune diseases, immune mediated necrotizing myopathy (IMNM), inclusion-body myositis or cancer-associated myositis - End-stage IIM wherein muscle weakness is most likely due to muscle damage, rather than myositis disease activity - Increased risk of major cardiovascular problems - Current smoker or smoked for a long time in the past - Pregnancy or lactation - Previous use of other JAK inhibitors - Use of any investigational drug within one month prior to screening or within five half-lives of the investigational agent, whichever is longer. - Human Immunodeficiency Virus (HIV) infection - Presence of an active infection or viral hepatitis type B or C - History of shingles or recurrent herpes simplex infection - Concomitant malignancies or previous malignancies within the last five years (with exception of adequately treated basal or squamous cell carcinoma of the skin) - Increased risk of cancer - Kidney injury with estimated glomerular filtration rate <15mL/min/1.73m2 - Liver failure Child Pugh C - Absolute neutrophil count <1*109 - Absolute leukocyte count <0.5*109 - Hemoglobin <5mmol/L - Inability to comply with study and/or follow-up procedures - Known recent substance abuse (drugs or alcohol). - Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period. - Previous non-adherence to immunosuppressants - Hypersensitivity to the active substance or to any of the excipients - Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Filgotinib
Filgotinib

Locations

Country Name City State
Netherlands Amsterdam UMC Amsterdam
Netherlands Hagaziekenhuis Den Haag
Netherlands Zuyderland Medical Center Heerlen
Netherlands Radboud university medical center Nijmegen
Netherlands Erasmus MC Rotterdam
Netherlands University Medical Center Utrecht

Sponsors (4)

Lead Sponsor Collaborator
UMC Utrecht Alfasigma S.p.A., Autoimmune Research and Collaboration Hub, ReumaNederland

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary EQ-5D-5L Change from baseline in EuroQoL-5D-5L 26 weeks
Primary Disease activity in Behcet's patients Change from baseline in Behcet's Disease Current Activity Form (BDCAF) 26 weeks
Primary Disease activity in myositis patients Change from baseline in Total Improvement Score (TIS) of the International Myositis Assessment Clinical Studies (IMACS) group 26 weeks
Primary Disease activity in IgG4-RD patients Change from baseline in IgG4-RD responder index 26 weeks
Secondary Corticosteroid toxicity Change from baseline in Glucocorticoid Toxicity Index (GTI) 26 weeks
Secondary Corticosteroid dosage Change from baseline in glucocorticoid dose 26 weeks
Secondary VAS score of pain Change from baseline in pain scores on the Visual Analog Scale (0-100mm). A higher score is a worse outcome 26 weeks
Secondary Fatigue Change from baseline in fatigue scores on the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F). A higher score is a worse outcome 26 weeks
Secondary Treatment-related adverse events Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 26 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05833711 - Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy Phase 2
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT04208464 - JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIM Phase 2
Completed NCT03267277 - Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Phase 2/Phase 3
Recruiting NCT06316076 - Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases Phase 1
Not yet recruiting NCT06350110 - Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE) Phase 1/Phase 2
Recruiting NCT05879419 - Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Phase 4
Recruiting NCT04792931 - Adult Autoimmune Myopathies (MAIA) N/A
Not yet recruiting NCT06417398 - Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Early Phase 1
Recruiting NCT04664465 - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Not yet recruiting NCT06152172 - CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101 Phase 1
Recruiting NCT05400889 - Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies Phase 2
Completed NCT03918356 - Application of Electrical Impedance Myography (EIM) as a Potential Biomarker of Idiopathic Inflammatory Myopathies N/A
Completed NCT00341679 - Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases
Recruiting NCT05952531 - Characterizing Myositis With 68Ga-FAPI PET/CT Early Phase 1
Recruiting NCT05200702 - Assessment of Safety and Acute Effects of a Knee-hip Powered Soft Exoskeleton in Patients With Neuromuscular Disorders N/A
Completed NCT03092167 - Physical Training in Patients With Idiopathic Inflammatory Myopathies N/A
Recruiting NCT03092180 - Optimizing Treatment on Idiopathic Inflammatory Myopathies
Recruiting NCT05199246 - Assessment of Safety and Acute Effects of a Lower-limb Powered Dermoskeleton in Patients With Neuromuscular Disorders N/A
Not yet recruiting NCT04034199 - Treating Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density With Denosumab or Zoledronic Acid Phase 3